Pretargeting is a novel two-step approach which uses monoclonal antibodies or protein fragments to “paint the target” for targeted alpha particles radiation. Antibodies or protein fragments have a high affinity for specific tumor cells but clear slowly from the blood, so are not ideal radiopharmaceuticals. Pre-targeting using our proprietary Cuburbit[7]uril-admantane (CB7-Adma) pre-targeting platform involves two-steps. First, a Cuburbit[7]uril-antibody that binds with high specificity to a cancer-specific protein is administered via intravenous injection. This non-radioactive antibody is chemically modified to include the CB7 chemical entity and accumulates over days at the tumor site. Then, radioactive Pb-212 anchored to an Adma ligand via Perspective’s proprietary chelator is administered. The Adma ligand binds to the CB7 group that is attached to the cancerous cells with remarkable specificity and affinity, concentrating the radiation dose selectively at the tumor sites. Because the Adma ligand is small, it clears very rapidly from the patient's body, limiting the off-target radiation exposure.
Perspective is currently evaluating this platform in preclinical studies with multiple targets.
Perspective's pre-targeting platform has the potential to transform a large range of existing molecules and targets into “radio-antibody drug conjugates” with superior efficacy and reduced toxicity.
Perspective Therapeutics' Laboratories, where Discovery Starts
Building on Perspective's proprietary chelator as a platform technology for isotopes of lead, our discovery group based at the BioVentures Center in Coralville, IA, continues to innovate by developing novel molecules to new and emerging cancer-specific targets.
